Dr. Marc Hurlbert, a pharmacologist by training, was appointed Chief Executive Officer (CEO) for the Melanoma Research Alliance in May 2022. In this role, Marc is responsible for setting and executing the strategic direction of the organization and its science programs. Previous to his appointment as CEO, Dr. Hurlbert served as MRA's Chief Science Officer where he was responsible for guiding MRA’s scientific strategy, overseeing the grant-making program, and forging scientific collaborations. Under his leadership, MRA dramatically expanded investment in and focus on rare melanoma subtypes, brain metastases and leptomeningeal disease and broadened support for prevention and early detection of melanoma through novel technologies such as machine learning. He has more than 20 years of nonprofit and grant-making experience focused on advancing medical research. Past work has included treatment and prevention strategies for breast cancer, lymphoma and multiple myeloma, as well as juvenile diabetes.
